This Article Full Text Full Text (PDF) All Versions of this Article: 28/11/1909    most recent ATVBAHA.107.161240v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aukrust, P. Articles by Damås, J. K. Search for Related Content PubMed PubMed Citation Articles by Aukrust, P. Articles by Damås, J. K. Related Collections Chemokines in ATVB

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:1909.)
© 2008 American Heart Association, Inc.

Brief Reviews

Chemokines and Cardiovascular Risk

Pål Aukrust; Bente Halvorsen; Arne Yndestad; Thor Ueland; Erik Øie; Kari Otterdal; Lars Gullestad; Jan K. Damås

From the Research Institute for Internal Medicine (P.A., B.H., A.Y., T.U., E.Ø., KJ.O., J.K.D.), the Section of Clinical Immunology and Infectious Diseases (P.A., J.K.D.), the Section of Endocrinology (T.U.), and the Department of Cardiology (E.Ø., L.G.), Rikshospitalet University Hospital, University of Oslo, Norway.

Correspondence to Pål Aukrust, Section of Clinical Immunology and Infectious Diseases, Medical Department, Rikshospitalet University Hospital, University of Oslo, Sognsvannsveien 20, 0027 Oslo, Norway. E-mail pal.aukrust{at}rikshospitalet.no

Series Editor: Christian Weber
ATVB In Focus

Chemokines in Atherosclerosis, Thrombosis, and Vascular Biology

Based on the importance of inflammation in atherogenesis, recent work has focused on whether plasma markers of inflammation can noninvasively diagnose and prognosticate atherosclerotic disorders. Although several studies support an important pathogenic role of chemokines in atherosclerosis, potentially representing attractive therapeutic targets in atherosclerotic disorders, this does not necessarily mean that chemokines are suitable parameters for risk prediction. In fact, the ability to reflect upstream inflammatory activity, stable levels in individuals, and high stability of the actual protein (eg, long half-life and negligible circadian variation) are additional important criteria for an ideal biomarker in cardiovascular disease. Although plasma/serum levels of certain chemokines (eg, interleukin- 8/CXCL8 and monocyte chemoattractant protein-1/CCL2) have shown to be predictive for future cardiac events in some studies, their role as clinical biomarkers is unclear, and their ability to predict subclinical atherosclerosis has been disappointing. Further prospective studies, including a larger number of patients, are needed to make any firm conclusion. Based on the participation of several chemokines in atherogenesis, it is possible that in the future, combined measurements of multiple chemokines could reveal as a "signature of disease" that can serve as a highly accurate method to assess for the presence of atherosclerotic disease.

Key Words: chemokines • atherosclerosis • biomarkers • inflammation

This article has been cited by other articles:

				J. L. Martin-Ventura, J. Madrigal-Matute, B. Munoz-Garcia, L. M. Blanco-Colio, M. Van Oostrom, G. Zalba, A. Fortuno, C. Gomez-Guerrero, L. Ortega, A. Ortiz, et al. Increased CD74 expression in human atherosclerotic plaques: contribution to inflammatory responses in vascular cells Cardiovasc Res, August 1, 2009; 83(3): 586 - 594. [Abstract] [Full Text] [PDF]

				A. M. Jansson, P. Aukrust, T. Ueland, C. Smith, T. Omland, M. Hartford, and K. Caidahl Soluble CXCL16 Predicts Long-Term Mortality in Acute Coronary Syndromes Circulation, June 30, 2009; 119(25): 3181 - 3188. [Abstract] [Full Text] [PDF]

				J. I. Borissoff, H. M.H. Spronk, S. Heeneman, and H. ten Cate Is thrombin a key player in the 'coagulation-atherogenesis' maze? Cardiovasc Res, June 1, 2009; 82(3): 392 - 403. [Abstract] [Full Text] [PDF]